JP2022529343A5 - - Google Patents
Info
- Publication number
- JP2022529343A5 JP2022529343A5 JP2021561625A JP2021561625A JP2022529343A5 JP 2022529343 A5 JP2022529343 A5 JP 2022529343A5 JP 2021561625 A JP2021561625 A JP 2021561625A JP 2021561625 A JP2021561625 A JP 2021561625A JP 2022529343 A5 JP2022529343 A5 JP 2022529343A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025083321A JP2025124703A (ja) | 2019-04-16 | 2025-05-19 | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU101183 | 2019-04-16 | ||
| LU101183A LU101183B1 (en) | 2019-04-16 | 2019-04-16 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| PCT/EP2020/060692 WO2020212478A1 (en) | 2019-04-16 | 2020-04-16 | Novel mek-inhibitor for the treatment of viral and bacterial infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083321A Division JP2025124703A (ja) | 2019-04-16 | 2025-05-19 | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529343A JP2022529343A (ja) | 2022-06-21 |
| JP2022529343A5 true JP2022529343A5 (https=) | 2023-04-21 |
Family
ID=66554457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561625A Pending JP2022529343A (ja) | 2019-04-16 | 2020-04-16 | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 |
| JP2025083321A Pending JP2025124703A (ja) | 2019-04-16 | 2025-05-19 | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083321A Pending JP2025124703A (ja) | 2019-04-16 | 2025-05-19 | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12350244B2 (https=) |
| EP (1) | EP3955908B1 (https=) |
| JP (2) | JP2022529343A (https=) |
| KR (1) | KR20210153642A (https=) |
| CN (1) | CN114007598A (https=) |
| AU (1) | AU2020258002B2 (https=) |
| BR (1) | BR112021020605A2 (https=) |
| CA (1) | CA3136171A1 (https=) |
| EA (1) | EA202192454A1 (https=) |
| ES (1) | ES3012533T3 (https=) |
| LU (1) | LU101183B1 (https=) |
| MX (1) | MX2021012604A (https=) |
| WO (1) | WO2020212478A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| CN119931962B (zh) * | 2025-04-07 | 2025-08-05 | 北京华诺泰生物医药科技有限公司 | 一种人偏肺病毒的培养方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000040237A1 (en) * | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| KR20020012315A (ko) * | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| WO2014056894A1 (en) | 2012-10-08 | 2014-04-17 | Westfaelische Wilhelms-Universitaet Muenster | Mek inhibitors in the treatment of virus diseases |
| CN113398271A (zh) | 2014-05-16 | 2021-09-17 | 归属疗法有限公司 | 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略 |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| KR20220074869A (ko) * | 2019-08-27 | 2022-06-03 | 아트리바 테라퓨틱스 게엠베하 | Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합 |
| JP7802365B2 (ja) * | 2019-10-08 | 2026-01-20 | アトリバ セラピューティクス ゲーエムベーハー | ハンタウイルス感染症の処置のためのｍｅｋ阻害剤 |
| EP3912623B1 (en) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2019
- 2019-04-16 LU LU101183A patent/LU101183B1/en active IP Right Grant
-
2020
- 2020-04-16 ES ES20724748T patent/ES3012533T3/es active Active
- 2020-04-16 WO PCT/EP2020/060692 patent/WO2020212478A1/en not_active Ceased
- 2020-04-16 AU AU2020258002A patent/AU2020258002B2/en active Active
- 2020-04-16 MX MX2021012604A patent/MX2021012604A/es unknown
- 2020-04-16 JP JP2021561625A patent/JP2022529343A/ja active Pending
- 2020-04-16 EA EA202192454A patent/EA202192454A1/ru unknown
- 2020-04-16 EP EP20724748.7A patent/EP3955908B1/en active Active
- 2020-04-16 CA CA3136171A patent/CA3136171A1/en active Pending
- 2020-04-16 BR BR112021020605A patent/BR112021020605A2/pt not_active Application Discontinuation
- 2020-04-16 US US17/604,355 patent/US12350244B2/en active Active
- 2020-04-16 CN CN202080044394.4A patent/CN114007598A/zh active Pending
- 2020-04-16 KR KR1020217036169A patent/KR20210153642A/ko active Pending
-
2025
- 2025-05-19 JP JP2025083321A patent/JP2025124703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529343A5 (https=) | ||
| JP2020506243A5 (https=) | ||
| Boltz et al. | Drugs in development for influenza | |
| RU2019126746A (ru) | Способы лечения гриппа | |
| Leneva et al. | Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol | |
| Chen et al. | Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice | |
| CN102438604B (zh) | 高致病性传染性疾病的预防及治疗制剂 | |
| MX2012007410A (es) | Compuestos antivirales novedosos. | |
| JP2009535352A5 (https=) | ||
| BRPI0807597B1 (pt) | composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação | |
| JP2010285436A5 (https=) | ||
| EP4329743A1 (en) | Pyruvate esters for the treatment of viral diseases | |
| TW202110461A (zh) | 流行性感冒病毒感染症或冠狀病毒感染症之預防及/或治療劑 | |
| CN114007598A (zh) | 用于治疗病毒和细菌感染的新型mek抑制剂 | |
| Casanova et al. | N-Acetylcysteine: An old drug with variable anti-influenza properties | |
| EA202092814A1 (ru) | Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства | |
| CN105246484B (zh) | 马替麦考酚酯或其盐类用于制备抗流感病毒之药物的用途 | |
| Leyva-Grado et al. | Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses | |
| Kacergius et al. | Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and gamma interferon-activated RAW 264.7 macrophages. | |
| Wang | Recent advances in the discovery and development of anti-influenza drugs | |
| Liu et al. | Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir) | |
| CN101842092A (zh) | 用于治疗流感感染的材料和方法 | |
| CA3184167A1 (en) | Azelastine as antiviral treatment | |
| Shokouhi Targhi et al. | In vitro anti-influenza assessment of anionic compounds ascorbate, acetate and citrate | |
| GB2475359A (en) | A compound for use in treating a fulminant respiratory disorder |